Journal: medRxiv

Article Title: The impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity

doi: 10.1101/2024.01.31.24302065

Figure Lengend Snippet: a, Cohort timeline overview indicated by time post vaccination and vaccine regimen received. Participants received Dryvax, JYNNEOS, or both Dryvax and JYNNEOS vaccines and plasma samples were collected at the indicated time points. Participants were then stratified in five main groups: C0, non-vaccinated (C0=24); C1, Dryvax (C1=78); C2, JYNNEOS (C2=62); C3, Dryvax + JYNNEOS (C3=29); C4, Mpox-Infected patients (C4=25). Dryvax was administered as a single dose at least 40 years prior to this study, whereas the JYNNEOS regimen consisted of two vaccination doses and was recently administered to these participants. Created with BioRender. b,c, Plasma reactive IgG to viral antigens was measured across all full vaccinated individuals and non-vaccinated controls (C0-C3) (C0=12, C1=40, C2=59, C3=31). b, Plasma reactivity to VACV proteins B5R, A33R, A27L, and L1R. c, Plasma reactivity to MPXV proteins B6R, A35R, A29L, L1R and E8L. d,e, LOWESS regression analysis of virus-specific IgG levels over time following JYNNEOS vaccination. d, Plasma reactivity to VACV proteins. e, Plasma reactivity to MPXV proteins. Regression lines are shown as purple (JYNNEOS) and green (JYNNEOS + Dryvax); shading represents 95% confidence interval. For the JYNNEOS cohort, baseline controls consisted of non-vaccinated individuals. Baseline controls for the Dryvax + JYNNEOS cohort were individuals who had previously been vaccinated with Dryvax. Significance was assessed by one-way ANOVA corrected for multiple comparisons using Tukey’s method. Baseline: C2=12, C3=40; 7 days post 1 st vaccine dose: C2=31, C3=16; 30-60 days post 1 st vaccine dose C2=31, C3=14; 7 days post 2 nd vaccine dose: C2=30, C3=13; 30-60 days post 2 nd vaccine dose: C2=22, C3=14; 180-240 days post 2nd vaccine dose: C2=10, C3=4. Horizontal bars represent median fold change. Non-Vax, non-vaccinated; TP5:180+, 180-240 days. ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05.

Article Snippet: MaxiSorp plates (96 wells; 442404, Thermo Scientific) were coated with 50□μl per well of either recombinant MPox A35R (A3R-M52H3-100 μg, ACROBiosystems), MPox A29L (A2L-M52H3-100 μg, ACROBiosystems), MPox E8L (E8L-M52H3-50 μg, ACROBiosystems), MPox L1R (L1R-M5241-50 μg, ACROBiosystems), MPox H3L (H3L-M52H1-50 μg, ACROBiosystems), MPox A30L (A3L-M5243-50 μg, ACROBiosystems), VACV A33R (40896-V07E-100 μg, Sino Biological), VACV A27L (40897-V07E-100 μg, Sino Biological), VACV L1R (40903-V07H-100 μg, Sino Biological), or VACV OPC005 [vD8L] (CSB-EP322653VAA-100 μg, CusaBio) at a concentration of 2□μg/ml in PBS and were incubated overnight at 4□°C.

Techniques: Vaccines, Infection, Virus

Journal: medRxiv

Article Title: The impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity

doi: 10.1101/2024.01.31.24302065

Figure Lengend Snippet: Participants received the JYNNEOS vaccine and plasma samples were collected longitudinally at multiple points: baseline (prior to the JYNNEOS vaccination), 7-30 days after the first vaccine dose, and 7-240 days after the second dose. The participants were then categorized into two groups based on their previous vaccination history: 1) the JYNNEOS group, consisting of naïve, non-vaccinated individuals who received the JYNNEOS regimen; and 2) the Dryvax + JYNNEOS group, comprising individuals who were previously vaccinated with Dryvax and subsequently received the JYNNEOS regimen. Importantly, for the JYNNEOS cohort, baseline consists of non-vaccinated individuals. Baseline controls for the Dryvax + JYNNEOS cohort were individuals who had previously been vaccinated with Dryvax. a,b,c,d Plasma reactivity to VACV proteins B5R, A33R, A27L, and L1 (top panel) and to MPXV proteins B6R, A35R, A29L, L1R and E8L (bottom panel). JYNNEOS: Baseline=12; Dose 1=62; Dose 2=62; JYNNEOS + Dryvax: Baseline=40; Dose 1= 30; Dose 2= 31. a, Plasma virus-specific IgG responses on naïve, non-vaccinated individuals following JYNNEOS vaccine doses. b, Plasma virus-specific IgG responses on individuals previously vaccinated with Dryvax and boosted with the JYNNEOS vaccine doses. c, Comparison of baseline plasma virus-specific IgG levels with those measured at the final collection time point (180-240 days post the second vaccination dose), in naïve, non-vaccinated individuals who received the JYNNEOS vaccine regimen. d, Comparison of baseline plasma virus-specific IgG levels with those measured at the final collection time point (180-240 days post the second vaccination dose) on individuals previously vaccinated with Dryvax and boosted with the JYNNEOS vaccine doses. Significance was assessed by one-way ANOVA corrected for multiple comparisons using Tukey’s method. JYNNEOS: Baseline=12; 180-240 days=10; JYNNEOS + Dryvax: Baseline=40; 180-240 days=4. Each dot represents a single individual. Horizontal bars represent median fold change. Boxes represent average ± SD. TP5:180+, 180-240 days. ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05.

Article Snippet: MaxiSorp plates (96 wells; 442404, Thermo Scientific) were coated with 50□μl per well of either recombinant MPox A35R (A3R-M52H3-100 μg, ACROBiosystems), MPox A29L (A2L-M52H3-100 μg, ACROBiosystems), MPox E8L (E8L-M52H3-50 μg, ACROBiosystems), MPox L1R (L1R-M5241-50 μg, ACROBiosystems), MPox H3L (H3L-M52H1-50 μg, ACROBiosystems), MPox A30L (A3L-M5243-50 μg, ACROBiosystems), VACV A33R (40896-V07E-100 μg, Sino Biological), VACV A27L (40897-V07E-100 μg, Sino Biological), VACV L1R (40903-V07H-100 μg, Sino Biological), or VACV OPC005 [vD8L] (CSB-EP322653VAA-100 μg, CusaBio) at a concentration of 2□μg/ml in PBS and were incubated overnight at 4□°C.

Techniques: Virus, Comparison